MarketLens
Sign Up

What Prompted Vivo Capital's Exit from Cidara Therapeutics

5 months ago
SHARE THIS ON:

What Prompted Vivo Capital's Exit from Cidara Therapeutics

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 week ago

Vir Biotechnology Appoints David Liu as Chief Medical Officer

Vir Biotechnology appointed David Liu as Executive Vice President and Chief Medical Officer, effective immediately, filling a key clinical leadership role. The move brings a new executive to oversee t...
News•3 months ago

U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China

U.S. biotechs are tightening controls on proprietary data and processes to slow China's fast-follower drug development, shifting competitive strategy.
Stock News•3 months ago

Evommune's Healthy Balance Sheet Buys Them Time For AD

Evommune's EVO756 CSU miss casts doubt on its pipeline, but a healthy balance sheet and positive Phase 2a AD data for EVO301 provide a potential catalyst.

Breaking News

View All →

Top Headlines

View More →
Stock News•51 minutes ago

Thinking Nvidia Stock Could Hit $10 Trillion? Here's 1 Reason I'd Be Cautious

Stock News•1 hour ago

Nvidia (NVDA) Exceeds Market Returns: Some Facts to Consider

Stock News•1 hour ago

Amazon: Wall Street Is Missing The Bigger Picture

Stock News•1 hour ago

Deadline Alert: Alphabet Inc. Investors Have Until December 1, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds

Stock News•1 hour ago

Former Google CEO Schmidt owns 1% stake in Anthropic, Bloomberg reports